Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

Group 1 - Verona Pharma plc has launched its COPD drug Ohtuvayre (ensifentrine) and is only three quarters into the launch phase, indicating potential for significant market impact [1] - The discussion surrounding Ohtuvayre as a blockbuster drug is gaining traction, suggesting optimism about its future performance [1] Group 2 - The company operates in the biotech sector, focusing on trading around key events such as trial results and regulatory approvals [1]